Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective randomized trial to compare two rituximab regimens for adult refractory nephrotic syndrome (OPTIMALNS)
jRCTs051180180Completed
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised trial of rituximab in nephrosis and focal segmental glomerulosclerosis (FSGS) (2 arms). Primary endpoint: Number of relapse. Started Nov 2015; status: completed.
02
Drugs
rituximab
03
Conditions
nephrosisfocal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on jRCTs051180180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180180.